AstraZeneca (NYSE:AZN) ADRs fell as much as 5.4% on Thursday after it announced that US regulators had dealt it a setback by putting a temporary halt to enrolling new patients with certain cancers in clinical trials involving its new drug durvalumab.
AstraZeneca said that the US Food and Drug Administration’s partial hold was limited to patients with head and neck cancer, following bleeding concerns.
The company said that it expects “pivotal data” on durvalumab’s effect on lung cancer in the first half of new year.
AstraZeneca shares were last seen down 3.9% at $28.43.
Story by ProactiveInvestors